DarioHealth, a digital chronic-condition management platform, has partnered with an unnamed pharmaceutical company to support its direct-to-consumer strategy using DarioConnect (formerly Twill Care). This collaboration leverages Dario’s patient engagement and navigation tools to help onboard patients eligible for the pharma company’s new psoriasis medication, fostering engagement and gathering critical insights on patient outcomes and drug effectiveness.
The agreement also involves a consumer health platform that enables patients to aggregate their medical records in one place, providing the pharma partner with de-identified, aggregate data to monitor treatment outcomes and track prescription trends. Financially, the partnership begins with Dario receiving an initial configuration fee, followed by a subscription for platform and services, allowing DarioConnect to continue directing engaged patients to the pharma company’s digital channels.
“Dario Connect's approach is set to transform how pharma companies interact with patients, offering data-driven insights and support that could reshape healthcare,” stated Steven Nelson, DarioHealth’s Chief Commercial Officer.
In recent developments, DarioHealth has expanded its offerings by integrating Twill’s condition-specific communities into its cardiometabolic platform after acquiring Twill in February for $22.4 million. Additionally, DarioHealth signed a multimillion-dollar Medicare Advantage contract set to launch in January 2025, expected to boost recurring revenue. It also secured a contract with a Medicaid health plan, offering its full suite of cardiometabolic solutions. In Q2 2024, DarioHealth reported a 1.7% revenue increase year-over-year, primarily driven by growth in its B2B2C channel.
Click here to read the original news story.